1 / 4

MASS-II 10 year

MASS-II 10 year. Objective: To evaluate the relative efficacies of the three therapeutic strategies in patients with stable angina , preserved LVF and MVD, MT, PCI or CABG. Study: Single center randomized trial.

ruby
Download Presentation

MASS-II 10 year

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. MASS-II 10 year Objective: To evaluate the relative efficacies of the three therapeutic strategies in patients with stable angina, preserved LVF and MVD, MT, PCI or CABG. Study: Singlecenter randomized trial. Population: Patients with angina CCS II-III, proximal multivesseldisease and documented ischemia, suitable for both PCI and CABG. Endpoint: Composite of mortality, Q-wave myocardial infarction, refractory angina requiring revascularization.

  2. Medical therapy n=203 Patients randomized n=611 90% LAD disease 41% 2 vessel 58 % 3 vessel PCI n=205 CABG n=203 MASS-II 10 year

  3. MASS-II 10 year Event rate at f-up (%) p=0.089 p=0.01 p =0.001 p<0.001 p < 0.001 HR foroccurrence of compositeend-point (Cox regression): CABG vs MT: 0.43 (0.32-0.56) p=0.001 CABG vs PCI: 0.54 (0.4-0.72) p=0.001 MT vs PCI: 1.27 (0.99-1.62) p=0.06

  4. MASS-II 10 year Conclusion: At 10 year follow-up the MASS II trial showed the benefits of CABG and PCI over MT with regard to several clinical end-points, although with similar rates of overall mortality. CABG was associated with a higher rate of event free survival. Hueb et al. Circulation 2010;122:949-57

More Related